Overview

A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

Status:
Not yet recruiting
Trial end date:
2023-04-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the humoral immunogenicity and safety of 2 doses of GSK Biologicals' Herpes Zoster subunit vaccine (HZ/su) administered for the prevention of Herpes Zoster (HZ) in adults aged 50 years of age (YOA) or older from India.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline